Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 1, 2012, Pages 93-108

  Rufo, Paul A ^a   Denson, Lee A ^b   Sylvester, Francisco A ^c   Szigethy, Eva ^d   Sathya, Pushpa ^e   Lu, Ying ^f   Wahbeh, Ghassan T ^g   Sena, Laureen M ^a   Faubion, William A ^h  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Division of Pediatric Infectious Diseases   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f Northwell Health   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h MAYO CLINIC   (United States)

Author keywords

Crohn disease; health supervision; inflammatory bowel disease; preventive care; primary care; ulcerative colitis

Indexed keywords

25 HYDROXYVITAMIN D; ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CALCIUM; CALGRANULIN; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ERGOCALCIFEROL; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; OSELTAMIVIR; PHOSPHORUS; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VACCINE; VITAMIN D;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ACNE; ADOLESCENT; ANAMNESIS; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BASAL CELL CARCINOMA; BLOOD LEVEL; BODY HEIGHT; BODY WEIGHT; BONE ATROPHY; BONE MARROW TOXICITY; CALCIUM INTAKE; CANCER SCREENING; CHILD; CHILD HEALTH CARE; CHILL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC TEST; DIARRHEA; DIETARY INTAKE; DRUG ERUPTION; DRUG FEVER; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERIC FEEDING; ENTERITIS; FACE EDEMA; FATIGUE; FECES ANALYSIS; FOOD COMPOSITION; FOOD INTAKE; GASTROINTESTINAL ENDOSCOPY; GENETIC COUNSELING; GLUCOSE INTOLERANCE; GROWTH DISORDER; HEADACHE; HEMATOCHEZIA; HEPATITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFLUENZA; INJECTION SITE REACTION; LABORATORY TEST; LIVER TOXICITY; MALAISE; MENTAL HEALTH; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; OUTPATIENT CARE; PANCREATITIS; PARENTERAL NUTRITION; PATIENT COUNSELING; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; PHYSICAL DEVELOPMENT; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DEVELOPMENT; QUALITY OF LIFE; RADIODIAGNOSIS; RATING SCALE; REMISSION; RICKETS; SEIZURE; SHIGELLOSIS; SIDE EFFECT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; ULCERATIVE COLITIS; URINALYSIS; URTICARIA; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; CALCIUM, DIETARY; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DIET; DIETARY SUPPLEMENTS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MALE; MEDICAL HISTORY TAKING; NUTRITION ASSESSMENT; PHYSICAL EXAMINATION; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D;

EID: 84862318157     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31825959b8     Document Type: Article

References (125)

1. Deleted in proof.
2. Deleted in proof.
3. Armitage E, Drummond H, Ghosh S, et al. InciDence of juvenile-onset Crohn's disease in Scotland. Lancet 1999;353:1496-7.
4. Turunen P, Kolho KL, Auvinen A, et al. InciDence of inflammatory bowel disease in Finnish children 1987-2003. Inflamm Bowel Dis 2006;12:677-83.
5. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease inWiscons: a statewide population-based study. J Pediatr 2003;143:525-31.
6. Grieci T, Butter A. The inciDence of inflammatory bowel disease in the pediatric population of Southwestern Ontario. J Pediatr Surg 2009;44:977-80.
7. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149:916-24.
8. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003;32:967-95.
9. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:839-49.
10. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004;126:1550-60.
11. Palm O, Moum B, Jahnsen J, et al. The prevalence and inciDence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001;40:1256-61.
12. Barclay AR, Keightley JM, Horrocks I, et al. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:677-83.
13. Standridge S, de los Reyes E. Inflammatory bowel disease and cerebrovascular arterial and venous thromboembolic events in 4 pediatric patients: a case series and review of the literature. J Child Neurol 2008;23:59-66.
14. Rahhal RM, Pashankar DS, Bishop WP. Ulcerative colitis complicated by ischemic colitis and Budd Chiari syndrome. J Pediatr Gastroenterol Nutr 2005;40:94-7.
15. Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1755-64.
16. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-12.
17. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
18. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009;48:48-54.
19. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28:1221-9.
20. Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007; 50:1697-706.
21. Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009;251:751-61.
22. Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CTenterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009;193:113-21.
23. Essary B, Kim J, Anupindi S, et al. Pelvic MRI in children with Crohn disease and suspected perianal involvement. Pediatr Radiol 2007; 37:201-8.
24. Darbari A, Sena L, Argani P, et al. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD. Inflamm Bowel Dis 2004;10:67-72.
25. Alison M, Kheniche A, Azoulay R, et al. Ultrasonography of Crohn disease in children. Pediatr Radiol 2007;37:1071-82.
26. Potthast S, Rieber A, Von Tirpitz C, et al. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002;12:1416-22.
27. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84.
28. Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009;169:2071-7.
29. Gaca AM, Jaffe TA, Delaney S, et al. Radiation doses from smallbowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatr Radiol 2008;38:285-91.
30. Caprilli R, Gassull MA, Escher JC, et al. European eviDence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 (suppl 1):i36-58.
31. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available eviDence. Inflamm Bowel Dis 2003;9:34-58.
32. Travis SP, Stange EF, Lemann M, et al. European eviDence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 (suppl 1):i16-35.
33. Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523-7.
34. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80.
35. Ceyhan BB, Karakurt S, Cevik H, et al. Bronchial hyperreactivity and allergic status in inflammatory bowel disease. Respiration 2003; 70:60-6.
36. Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med 2000;161:1051-4.
37. Raj AA, Birring SS, Green R, et al. Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008;102:780-5.
38. Bernstein CN,Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a populationbased study. Gastroenterology 2005;129:827-36.
39. Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14:1425-31.
40. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
41. Mintz R, Feller ER, Bahr RL, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:135-9.
42. de Jong DJ, Tielen J, Habraken CM, et al. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm Bowel Dis 2005;11:972-6.
43. Yakut M, Ustun Y, Kabacam G, et al. Serum vitamin B(12) and folate status in patients with inflammatory bowel diseases. Eur J Intern Med 2010;21:320-3.
44. Nishi Y, Lifshitz F, Bayne MA, et al. Zinc status and its relation to growth retardation in children with chronic inflammatory bowel disease. Am J Clin Nutr 1980;33:2613-21.
45. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone Density and structure in an inciDent cohort of children with Crohn's disease. Gastroenterology 2009;136:123-30.
46. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral Density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:42-50.
47. Zemel BS, Leonard MB, Kelly A, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and Density in children. J Clin Endocrinol Metab 2010;95:1265-73.
48. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115-21.
49. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 2011;12:4-18.
50. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122:398-417.
51. Szigethy E, McLafferty L, Goyal A. Inflammatory bowel disease. Child Adolesc Psychiatr Clin N Am 2010;19:301-18.
52. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a crosssectional study. J Pediatr Gastroenterol Nutr 2004;39:395-403.
53. Mackner LM, Crandall WV. Long-term psychosocial outcomes reported by children and adolescents with inflammatory bowel disease. Am J Gastroenterol 2005;100:1386-92.
54. Nicholas DB, Otley A, Smith C, et al. Challenges and strategies of children and adolescents with inflammatory bowel disease: a qualitative examination. Health Qual Life Outcomes 2007;5:28.
55. Otley AR, Griffiths AM, Hale S, et al. Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis 2006;12:684-91.
56. Perrin JM, Kuhlthau K, Chughtai A, et al. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr 2008;46:164-71.
57. Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1755-64.
58. Sitarenios GM. Kovacs M. Use of the Children's Depression Inventory. In: Maruish ME, ed. Psychological Testing for Treatment Planning and Outcomes Assessment. 2nd ed. Mahwah, NJ: Lawrence Erlbaum Associates; 1999:267-98.
59. Garcia-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. Behav Res Ther 2004;42:367-83.
60. Milne B, Joachim G, Niedhardt J. A stress management programme for inflammatory bowel disease patients. J Adv Nurs 1986;11:561-7.
61. Mussell M, Bocker U, Nagel N, et al. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol 2003;38:755-62.
62. Wahed M, Corser M, Goodhand JR, et al. Does psychological counseling alter the natural history of inflammatory bowel disease? Inflamm Bowel Dis 2010;16:664-9.
63. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology 2003;125:1290.
64. Kast RE, Altschuler EL. Bone Density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Gut 2004;53:1056.
65. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis 2007;13:225-34.
66. Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry 2007;46:1290-8.
67. Mawdsley JE, Jenkins DG, Macey MG, et al. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol 2008;103:1460-9.
68. Bers MU, Gonzalez-Heydrich J, Demaso DR. Use of a computer-based application in a pediatric hemodialysis unit: a pilot study. J Am Acad Child Adolesc Psychiatry 2003;42:493-6.
69. Demaso DR, Marcus NE, Kinnamon C, et al. Depression experience journal: a computer-based intervention for families facing childhood depression. J Am Acad Child Adolesc Psychiatry 2006;45:158-65.
70. Shepanski MA, Hurd LB, Culton K, et al. Health-related quality of life improves in children and adolescents with inflammatory bowel disease after attending a camp sponsored by the Crohn's and Colitis Foundation of America. Inflamm Bowel Dis 2005;11:164-70.
71. Szigethy E, Hardy D, Craig AE, et al. Girls connect: effects of a support group for teenage girls with inflammatory bowel disease and their mothers. Inflamm Bowel Dis 2009;15:1127-8.
72. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:677-92.
73. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834-40.
74. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:20-34.
75. Pickering L.Baker C.Kimberlin D et al.Varicella-Zoster Infections In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics
76. Olsen KO, Joelsson M, Laurberg S, et al. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86:493-5.
77. Olsen KO, Juul S, Bulow S, et al. Female fecundity before and after operation for familial aDenomatous polyposis. Br J Surg 2003;90:227-31.
78. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007;50:1128-38.
79. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984;25:52-6.
80. Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999;94:3236-8.
81. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113:802-7.
82. National Cancer Institute. Surveillance Epidemiology and End Results, in SEER. National Cancer Institute. http://seer.cancer.gov/csr/1975-2007/browse- csr.php.
83. Ekbom A. Risk of cancer in ulcerative colitis. J Gastrointest Surg 1998;2:312-3.
84. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
85. Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn's disease. A population study in central Israel. Scand J Gastroenterol 1989;24:346-50.
86. Gillen CD, Andrews HA, Prior P, et al. Crohn's disease and colorectal cancer. Gut 1994;35:651-5.
87. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-9.
88. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039-46.
89. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009;104:2222-32.
90. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007;34:380-5.
91. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by antitumor-necrosis-factor antibody therapy. Dermatology 2007;215:295-300.
92. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev Gastroenterol Disord 2003;3:S23-9.
93. Salliot C, Van Der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4.
94. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. JAm Acad Dermatol 2009;60:824-37.
95. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30.
96. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High inciDence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13.
97. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806.
98. American Academy of Pediatrics. Immunization, 2012 Schedules. http://www.aap.org/immunization/IZSchedule.html. Accessed May 24, 2012.
99. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010;50:562-5.
100. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30.
101. Pickering L.Baker C.Kimberlin D.et alCommittee on Infectious Diseases Influenza. In: Red Book: 2009 Report of the 28th ed. Elk Grove Village, IL: American Academy of Pediatrics 2009 400-12
102. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22.
103. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62.
104. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19:287-93.
105. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
106. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
107. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-2.
108. Siegel CA, MarDen SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis. Clin Gastroenterol Hepatol 2009;7:874-81.
109. Sweetser S, Schroeder KW, Pardi DS. Pseudomembranous colitis secondary to Klebsiella oxytoca. Am J Gastroenterol 2009;104:2366-8.
110. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006;101:2857-65.
111. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1432-42.
112. Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol 2010;105:1796-8.
113. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1788.
114. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009; 15:1218-23.
115. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009;1:1.
116. Atay O, Mahajan L, Kay M, et al. Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature. J Pediatr Gastroenterol Nutr 2009;49:196-201.
117. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008;68:255-66.
118. Neye H, Ensberg D, Rauh P, et al. Impact of high-resolution transabdominal ultrasound in the diagnosis of complications of Crohn's disease. Scand J Gastroenterol 2010;45:690-5.
119. Ripolles T, Martinez MJ, Paredes JM, et al. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology 2009;253:241-8.
120. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther 2006;24:1099-103.
121. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020-4.
122. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-85.
123. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009;29:855-62.
124. Imashuku S. Systemic type Epstein-Barr virus-related lymphoproliferative diseases in children and young adults: challenges for pediatric hemato-oncologists and infectious disease specialists. Pediatr Hematol Oncol 2007;24:563-8.
125. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.